First-Generation TRK Inhibitors: Clinical Evidence and Indications

In this podcast episode, listen to an engaging discussion between George D. Demetri, MD, and Alexander Drilon, MD, on key clinical trials leading to FDA approvals of first-generation TRK inhibitors, where these agents fit into treatment paradigms for various solid tumors, and considerations for choosing among currently available TRK inhibitors.